Tarsus Stock: Not Cheap, But XDEMVY Makes The Valuation Work (NASDAQ:TARS)
· seekingalpha.com
Tarsus Pharma trades at 3.3–3.5x 2026 guided sales, supported by 85% YoY sales growth and ~93% gross margin guidance. Learn why TARS stock is a buy.
About the TPT service
Thanks for reading. At the Total Pharma Tracker, we offer most of the following:-
For investors requiring hands-on support, our in-hou...